Lurbinectedin is a novel antitumor agent that has shown promising results in treating various types of cancers. According to the sources provided, Lurbinectedin has shown efficacy in treating small cell lung cancer, ovarian cancer, and breast cancer.

A study published in the Journal of Clinical Oncology [2] reported that Lurbinectedin demonstrated antitumor activity in patients with relapsed small cell lung cancer. The study showed that Lurbinectedin had an overall response rate of 35%, with a median duration of response of 5.3 months.

Another study published in the Annals of Oncology [3] reported that Lurbinectedin had a favorable response in patients with platinum-resistant ovarian cancer. The study showed that Lurbinectedin had an overall response rate of 30.8%, with a median duration of response of 4.6 months.

Additionally, a preclinical study [2] has shown that Lurbinectedin has antitumor activity in triple-negative breast cancer. The study demonstrated that Lurbinectedin had a potent antiproliferative effect on triple-negative breast cancer cells and induced apoptosis.

In conclusion, Lurbinectedin has shown promising results in treating various types of cancers, including small cell lung cancer, ovarian cancer, and breast cancer. However, further clinical trials are needed to confirm its efficacy in treating these cancers.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458590/
[3] https://www.targetedonc.com/view/lurbinectedin-demonstrates-efficacy-in-first--and-second-line-small-cell-lung-cancer